The new vaccines that protect older adults against RSV may be linked to a small ...
What does America’s crackdown on Chinese firms like WuXi mean for the U.S. biote...
This week on "The Readout LOUD": Are biotech's dog days over? What's a PIPE? And...
A House panel is hearing two bills that weaken different requirements in Medicar...
Novo Nordisk can barely make enough of Wegovy to satisfy demand for the dramatic...
In an interview with Pharmaceutical Technology, the company’s chief scientific o...
Biotechs need to navigate US-China relations when pursuing collaborations and dr...
IRA regulations have changed how pharma is approaching innovation in cancer drug...
As post-approval boundaries disproportionately affect rare disease patients, com...
The Phase III VELA programme will compare the IL-17 inhibitor sonelokimab to a p...
AbbVie will pay $48m in upfront costs and up to $665m in milestone payments to l...
The goal had been for 10,000 patients to be on Leqembi by the end of March 2024,...
AGTC-501 is in Phase II development for retinitis in the SKYLINE trial (NCT03316...
Regulatory standards concerning raw material selection are particularly stringen...
Whilst Minerva deals with clinical deficiencies, eyes turn to Karuna’s PDUFA dat...
An unprecedented shortage of cholera vaccine has public health experts fearing t...
